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CONCLUSIONS: An outcome guarantee is an acceptable
way for a nationally funded health service to partner a
pharmaceutical company for optimal diffusion of drugs
likely to beneﬁt a patient population. The model has
potential for replication in other therapeutic areas and
other healthcare systems.
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CRITIQUED ECONOMIC EVALUATIONS:THE
NHS ECONOMIC EVALUATION DATABASE
WITHIN THE HTA REVIEW PROCESS
Nixon J, Duffy SB, Craig D,Armstrong N, Christie J,
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York University,York, United Kingdom
OBJECTIVE: Outcomes in healthcare technology reviews
now increasingly include cost as well as effectiveness. The
aim of this study is to report the ﬁndings and implications
of a survey regarding the usefulness of NHS Economic
Evaluation Database (NHS EED) structured abstracts
within this process. METHODS: Postal survey of lead
authors of Technology Assessment Reviews (TARs) com-
missioned by the UK’s National Institute for Clinical
Excellence. The questionnaire investigated the usefulness
of NHS EED regarding: search strategy, data extraction,
quality assessment, and requirement for new modeling
studies. Qualitative data were requested, including opin-
ions regarding NHS EED. RESULTS: NHS EED was used
in 90% of all identiﬁed reviews (n = 46). The question-
naire response rate was 57%. The percentage of scores 3
or above, 2 or below, or N/A were, respectively: search
strategy = 60%, 22%, 17%; data extraction = 26%,
26%, 48%; quality assessment = 30%, 22%, 48%;
requirement for new modeling studies = 22%, 26%,
52%. The results were expanded upon in the qualitative
data from the respondents. CONCLUSIONS: Where
several economic evaluations had been published NHS
EED was utilized and valued as an independent source,
and was highly useful to non-economists. However, those
undertaking TARs also used conﬁdential data from
company submissions and cost data for studies not cri-
tiqued on NHS EED. More standardization and use of
quality checklists in reviews of economic studies is clearly
needed. The ﬁndings will help in developing and improv-
ing NHS EED in its role of providing health outcomes
and economic evidence in TARs.
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OBJECTIVE: To estimate the most costly disease condi-
tions affecting medical, absenteeism, and short term dis-
ability (STD) expenditures affecting a subset of American
employers. METHODS: The Medstat Group’s 1999
Health and Productivity Management (HPM) Database
was used for this analysis. The HPM database links
medical, pharmacy, STD, and absence claims for over
340,000 employees. Medstat’s Episode Grouping soft-
ware product was used to classify and organize employ-
ees’ inpatient, outpatient, emergency department (ED)
and pharmaceutical claims temporally, so they could 
be connected to the treatment of any given condition.
Absence and STD claims associated with each clinical
episode were then added. The most costly physical and
mental health conditions were then ranked by their
overall medical, pharmacy, absence and STD expendi-
tures. RESULTS: Across all physical health conditions,
employers paid an average of $2505 per eligible employee
for medical care (71% of total), $316 per employee for
STD (9% of total), and $703 per employee in absence
(20% of total). Medical care expenditures included
money for: inpatient care–$687 (20% of total), out-
patient care–$1321 (38% of total), ED treatment–$57
(2% of total), and pharmaceuticals–$440 (12% of total).
When considering per-eligible payments for mental health
conditions, $94 (53% of total) was paid through health
beneﬁts, $23 (13% of total) was paid through STD pro-
grams, and $61 (34% of total) was as a result of employee
absence from work. Medical expenditures for mental
health care included money for inpatient care–$21 (12%
of total), outpatient care–$45 (25% of total), ED treat-
ment–$0.3 (0.2% of total), and pharmaceuticals–$28
(15% of total). CONCLUSIONS: Although health care
expenditures account for the majority of costs faced by
American businesses, productivity-related costs can be
high as well. Inpatient, outpatient, ED, and drug cost,
along with STD and absence costs, varied greatly by
disease.
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OBJECTIVE: Falls are a major problem for the 
community-dwelling elderly. About 30% of this group
experience a fall each year and between 4 and 10% 
of community-dwelling elders experience a fall-related
injury. Further, falling occurrence is a signiﬁcant predic-
tor of institutionalization and death. The objective of this
study was to provide an annual estimate of the direct
medical costs associated with fall-related injuries among
the community dwelling elderly. The study was done from
the payer’s perspective. METHODS: Data from the 1997
Medical Expenditure Panel Survey (MEPS) were analyzed
to identify elderly respondents who reported a fall-related
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injury and to estimate the cost of treating those injuries.
Weighted analyses were used to produce estimates that
represented the cost of fall-related injuries in the civilian
non-institutionalized population in the United States 
for 1997. Cost estimates were based on actual reim-
bursements. Costs were estimated for inpatient hospital
care, emergency room visits, outpatient hospital services,
ofﬁce-based provider visits, dental care, home healthcare
and prescription drugs. RESULTS: In 1997, 2.9 million
individuals (9.0% of the non-institutionalized elderly
population) reported medical conditions related to 3.3
million falls. Fall-related medical care was provided to 2.3
million individuals. Of the reported fall-related injuries,
25.5% were fractures and 3.5% were hip fractures. Total
direct medical cost of fall-related care was $5.01 billion.
Mean values were $1521 per fall-related injury, $1716
per injured faller, and $2163 per patient receiving fall-
related care. The median expense per injured faller was
$151 and the maximum expense was $43,566. The most
frequently utilized services for fall-related care included
ofﬁce-based visits, prescription drugs, and emergency
room visits. Inpatient hospitalizations, while much less
utilized, accounted for nearly half of total costs. CON-
CLUSIONS: Fall-related injury is a common event for the
community-dwelling elderly and is associated with sub-
stantial direct medical costs.
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OBJECTIVES: To describe the characteristics and uti-
lization patterns of Medicaid patients with high health
care costs, and assess the risk factors associated with
those high cost recipients. METHODS: High cost reci-
pients were identiﬁed as those whose average monthly
Medicaid expense was in the upper 90 percentile of the
population. A sample of recipients consisting of 23,965
non-nursing home recipients (12,222 high cost recipients,
and 11,743 comparison recipients) were identiﬁed for this
study using retrospective data analysis of Ohio Medicaid
claims from January 1, 1999 to December 31, 2000.
Adjusted Clinical Groupâ software was used to catego-
rize population-based clinical characteristics for high
cost. Logistic regression analysis was conducted to assess
the risk factors associated with high cost recipients.
RESULTS: The average monthly costs were $2679 per
high cost recipient and $185 per comparison recipient.
Major cost components were hospitalization, prescription
drugs, mental health, physician encounters, and outpa-
tient care. For recipients age 64 or younger, the odds
ratios of the risk for high cost were: 1.35 (95% CI
1.26–1.46) for male recipients; 6.72 (CI 6.03–7.51) for
disabled or blind recipients, 1.8 (CI 1.64–1.97) for urban
recipients, 4.64 (CI 2.93–7.79) for recipients who died
during the study period, and 1.38 (CI 1.36–1.39) for each
additional comorbid condition. For recipients age 65 or
older, the odds ratios of the risk for high cost were: 5.89
(95% CI 3.61–10.0) for disabled or blind recipients, 1.96
(CI 1.40–2.78) for recipients who died during the study
period, and 1.2 (CI 1.36–1.39) for each additional comor-
bid condition. CONCLUSION: To prevent future health
care costs, it is important to focus on those high-risk
recipients with chronic diseases and many comorbidities,
being disabled/blind eligible, being male in Medicaid, and
living in urban areas through appropriate drug utilization
review or disease management programs.
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OBJECTIVES: To test the performance of an expanded
risk index based on pharmacy claims over longer time
periods than previous models. To investigate new alter-
native methods of handling skewed distributions of
medical cost data. METHODS: An expanded pharmacy
claims risk index was compiled from previous literature
and clinical review to include 50 chronic diseases. Each
disease state was assigned a weighted score based on rel-
ative clinical severity. Scores from each disease state were
totaled to obtain an overall risk score per member. The
score was applied to a continuously eligible adult popu-
lation (>18 years) of 116,371 members from a million
member mid-western Health plan between August 1,
1998 and July 31, 2001. A baseline pharmacy claims risk
score was calculated for August 1, 1998 through July 31,
1999 and used in conjunction with age and gender to
predict total costs of care (medical costs and pharmacy
costs combined) for the next 2 years using a split-sample
linear regression model building and validation tech-
nique. Various methods for handling non-normal dis-
tribution in the medical cost outcome where evaluated
including a new 2-part modeling approach. RESULTS:
The index was highly correlated with third year pharmacy
costs (spearman rho 0.65 p < 0.001) and moderately cor-
related with medical costs (Spearman rho 0.30 p < 0.001)
and all costs of care (Spearman rho 0.45 p < 0.001). Age
(categorical) and baseline pharmacy risk index (categori-
cal) were signiﬁcant predictors of third-year all costs of
care. The R2 for the linear 3-year model (0.05) was
improved signiﬁcantly by log transformation of the cost
outcome (R2 = 0.26) in both the estimation and valida-
tion samples. However a 2-part modeling approach 
may improve predictive precision. CONCLUSIONS: This
expanded pharmacy claims risk index is a signiﬁcant 
predictor of total costs of care two years from baseline.
